This HTML5 document contains 227 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34011740
rdf:type
wikibase:Item
schema:description
2014年论文 2014年論文 научна статия 2014 թվականի ապրիլին հրատարակված գիտական հոդված article scientific teaduslik artikkel videnskabelig artikel (udgivet 2014) vitskapeleg artikkel artigo científico (publicado na 2014) articolo scientifico vědecký článek artículo científico publicado en 2014 2014年論文 2014年论文 artigo científico 2014 nî lūn-bûn bài báo khoa học naučni članak mokslinis straipsnis 2014年论文 article científic სამეცნიერო სტატია บทความทางวิทยาศาสตร์ tieteellinen artikkeli мақолаи илмӣ vetenskaplig artikel tudományos cikk vedecký článok 2014년 논문 2014年論文 2014年论文 scienca artikolo artigo científico (publicado na 2014) artykuł naukowy artikulong pang-agham ২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ wissenschaftlicher Artikel 2014年論文 2014年论文 научная статья наукова стаття, опублікована у квітні 2014 مقالهٔ علمی 2014年論文 artículu científicu espublizáu en 2014 επιστημονικό άρθρο научни чланак мақолаи илмӣ 2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած articol științific 2014年の論文 scientific article مقالة علمية 2014年论文 מאמר מדעי wetenschappelijk artikel vitenskapelig artikkel article scientifique (publié 2014) научни чланак bilimsel makale سائنسی مضمون artikull shkencor
p:P577
wds:Q34011740-6381468D-9175-452B-B40C-BA0F0937FB0F
wdt:P577
2014-04-15T00:00:00Z
p:P407
wds:Q34011740-3491E86C-2975-44A4-A695-CE0141DCD295
wdt:P407
wd:Q1860
p:P2860
wds:Q34011740-04BABAF1-E3AB-478A-846F-5D04C5A6ADE7 wds:Q34011740-165029B0-C81C-49AC-9803-EBBE32FDF382 wds:Q34011740-1E4AB9E4-BA64-41E9-9A12-80CD16D1D31D wds:Q34011740-1EFC10B9-89AC-47CC-9044-FBA174C8823F wds:Q34011740-088A2834-4689-4C04-8EEE-76DB94956C8F wds:Q34011740-2B4306FA-5915-4BEF-8E73-9C5209B1E473 wds:Q34011740-2254948F-A712-4D0C-A367-6C7AF07F86E6 wds:Q34011740-251C41B7-69D9-4752-90A2-A5A443A69541 wds:Q34011740-29B7A7EF-5F5D-4303-A370-B64712CC9272 wds:Q34011740-4010D94E-C816-4073-996E-77C6AA747438 wds:Q34011740-4F19002C-ABA1-46D7-AEB2-48CE8E3E8635 wds:Q34011740-4F4DF251-22AB-4B1E-AB03-D7DEF097449E wds:Q34011740-39426E31-D24C-48B7-87FC-17556EB970FD wds:Q34011740-39F2A9DE-C81A-40D6-8A5E-9424473A5EC6 wds:Q34011740-3FD53BDF-8AC9-47A5-B21E-900D4BDD13A0 wds:Q34011740-5FF14033-51D3-407C-B504-E92187126D93 wds:Q34011740-68237ECB-BA82-4158-9A70-A2DEB0D026E0 wds:Q34011740-5131B27C-3AE6-4DC4-B2CD-C558F66526C8 wds:Q34011740-55CA59B1-A78D-4DB6-84F9-9B520E5C157B wds:Q34011740-76488419-3522-4F7C-93E6-8CECC0DF6B06 wds:Q34011740-7AEECE51-1698-4D3D-AC1A-7A391805526A wds:Q34011740-7F58A28A-4827-4748-8CE1-688B6AA42423 wds:Q34011740-82F33BFA-F85A-4DE6-B29B-FA2BE47E823B wds:Q34011740-6B0FF6C2-A003-469F-80A8-7CE29C707092 wds:Q34011740-706DDFEB-23FF-4FFF-BE4C-A9637BFE881E wds:Q34011740-737AF4F4-8115-43B2-B604-867556B93A84 wds:Q34011740-755235FE-D6DF-417C-8DFB-ADA953E67047 wds:Q34011740-8F65CE05-FCA8-4E16-9C24-DACBC78CC742 wds:Q34011740-902E0367-05E8-4940-88AB-A4FB2D7975E5 wds:Q34011740-934AC7C1-9A01-467A-AD99-875F4C485F28 wds:Q34011740-94FEBC4A-365B-47DD-9D51-CDC88C01DD79 wds:Q34011740-85D737F9-1204-42BD-912F-E9050C55F8F9 wds:Q34011740-8E87E36A-9F7B-416D-B085-F56B930673F0 wds:Q34011740-8EA0623D-87FF-4D1A-861C-D18DAD09B700 wds:Q34011740-A44285B8-C13F-46B6-89E8-5D870FB3EBCB wds:Q34011740-B1BE2704-92DC-4EAF-A049-4D7C687180FB wds:Q34011740-973039E0-568F-43C2-93E7-0CC1D53D16A0 wds:Q34011740-9B853714-5AA8-4900-9C77-1DAD4B12E038 wds:Q34011740-9C89322F-F11C-4973-A792-73F34F1F1BFE wds:Q34011740-BF43C323-55DD-469B-81FC-9D9523747B0F wds:Q34011740-C5888D6C-2F15-46DC-B316-92F27F4F9750 wds:Q34011740-D26CD548-CD1A-4C40-B280-8B123EB5AC8B wds:Q34011740-D2874AF0-4059-4CCE-BC3C-0D59985DEFE6 wds:Q34011740-B711AE79-70B1-488E-ADE6-B8A1F8843BEA wds:Q34011740-B8FA685D-3811-4BAC-AA4F-BB49AB469524 wds:Q34011740-DD7A54C5-8FCF-4E5B-BDDF-2D259D7A87DB wds:Q34011740-E2B1BF6E-52BD-44EA-911F-5930CBA3E2F5 wds:Q34011740-E758AC76-B110-4210-829A-05C2D83BCFD4 wds:Q34011740-F9ACA222-20D6-441C-96D2-42711BC71306 wds:Q34011740-D50CDB05-5BD8-4F07-964F-604E97D90C02 wds:Q34011740-D6BED3EF-9A67-4019-B160-6B5688B98098 wds:Q34011740-D7C12DC3-5D2B-4B19-8A4E-CF3A2EB520CE wds:Q34011740-FCEA62CF-64A2-475F-B40B-7121509CC10A
wdt:P2860
wd:Q24319174 wd:Q27860525 wd:Q40618806 wd:Q40303741 wd:Q44189526 wd:Q34612117 wd:Q34524219 wd:Q27851579 wd:Q27851423 wd:Q34523534 wd:Q34517403 wd:Q82366072 wd:Q73263471 wd:Q40534979 wd:Q40385638 wd:Q37919763 wd:Q72120035 wd:Q40252880 wd:Q46549470 wd:Q71841108 wd:Q37460343 wd:Q34054360 wd:Q37244802 wd:Q39895141 wd:Q46789222 wd:Q28242368 wd:Q35048217 wd:Q47665617 wd:Q34451540 wd:Q35127958 wd:Q40218888 wd:Q37373040 wd:Q27851469 wd:Q39981715 wd:Q34754329 wd:Q57986979 wd:Q27851417 wd:Q36449609 wd:Q42718734 wd:Q34517235 wd:Q40390558 wd:Q27851767 wd:Q39745611 wd:Q29042570 wd:Q34784925 wd:Q25938997 wd:Q27851415 wd:Q39895136 wd:Q34549807 wd:Q27824769 wd:Q27851430 wd:Q84337089 wd:Q40543180
p:P2093
wds:Q34011740-36E84381-46C8-40B9-AB74-21402FE4CE98
wdt:P2093
Yesid Alvarado
rdfs:label
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations
skos:prefLabel
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations
schema:name
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations
p:P50
wds:Q34011740-D8D58F8D-4AA2-4D64-BB47-5BF43F7C7E03 wds:Q34011740-50777EAE-464C-4C5B-8CEC-03EA6B491FA3 wds:Q34011740-5FFA6124-57F2-49FA-BDCE-28D0066C80A3 wds:Q34011740-26BD98C0-1670-4C85-AEB2-ADAAF7535D94 wds:Q34011740-08BE5667-0582-44AC-8F2C-9A5C07511F77 wds:Q34011740-1FE779F0-AD40-40B8-8150-ECA12E406F48 wds:Q34011740-B8B3E5A0-1538-478C-8EEB-840E29896E14 wds:Q34011740-BA4C7DD6-7117-4EA7-8AB4-952C16C6E23B wds:Q34011740-956E5808-ABF9-4A39-8252-D34D28372E03
wdt:P50
wd:Q64026337 wd:Q40614280 wd:Q60320900 wd:Q66370731 wd:Q66385413 wd:Q66385504 wd:Q114427908 wd:Q60394812 wd:Q89564940
p:P1476
wds:Q34011740-9F7FB7E6-A614-45B4-929E-D667B126B834
wdt:P1476
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations
p:P304
wds:Q34011740-B302EF08-A55D-40D4-9EAB-DBA89C6199AA
wdt:P304
2142-2149
p:P31
wds:Q34011740-8850C406-8D98-4AA2-933E-63233E88B5E1
wdt:P31
wd:Q13442814
p:P921
wds:Q34011740-38F87DA7-1DD1-4A6B-A2F0-F8BBA98D698C wds:Q34011740-4276CBD8-646E-4CCA-AB30-CED7F67F916E wds:Q34011740-FE2C8498-62C6-4E12-9087-18803FEE7900
wdt:P921
wd:Q29496 wd:Q264118 wd:Q181600
p:P698
wds:Q34011740-3BB69C95-C94F-4092-9933-D01A9FD87285
wdtn:P698
n11:24737502
wdt:P698
24737502
p:P1433
wds:Q34011740-FA9D6FFC-41AA-4F18-8A62-D8C51CBF06B0
wdt:P1433
wd:Q326041
p:P433
wds:Q34011740-58A40C27-0092-483E-BECF-81D3528BFFC5
p:P478
wds:Q34011740-FDE1DA16-150A-434C-8E83-A1D18D3CCD3C
wdt:P433
14
wdt:P478
120
p:P356
wds:Q34011740-11E5D035-E4A3-4832-9B2C-8F41D43049EE
wdtn:P356
n12:CNCR.28705
wdt:P356
10.1002/CNCR.28705
p:P932
wds:Q34011740-0A33B6E4-27D2-4530-AF87-40C4B5D3A757
wdt:P932
4124083